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The existence of a 15(S)-hydroxy-5,6-oxido-7,9,13-trans-1 I-cis-eicosatetraenoic acid intermediate in the bio- 
syntheses of lipoxins A and B has recently been proposed. In the present study, human leukocytes were 
exposed to 15HETE and the divalent cation ionophore A23187 and alcohol trapping studies were per- 
formed. The products containing alkyltetraenes were isolated and characterized. HPLC analysis, UV spec- 
troscopy and GC/MS of the products showed that 5,15_dihydroxy- 14-O-alkyleicosatetraenoic a ids were 
formed, indicating that 5(6)-epoxytetraenes (precursor of the trapping product) were formed in human leu- 
kocytes. To gain further evidence for the role of 5(6)-epoxytetraene intermediate in the biosynthesis of lipox- 
ins, (15)-hydroxy-5,6-oxido-7,9,13-trans-1 I-cti-eicosatetraenoic acid was prepared by total chemical synthe- 
sis. When added to purified human liver cytosolic epoxide hydrolase, the epoxide was rapidly and quantita- 
tively converted into LXA. The results provide further evidence for the role of a S(6)epoxytetraene interme- 
diate in the biosynthesis of lipoxins. 
Arachidonic acid Conjugated tetraene Lipoxygenase interaction product (Human) Leukocyte Epoxide 
1. INTRODUCTION 
The oxygenative metabolism of arachidonic acid 
appears to play an important role in a wide variety 
of inflammatory responses (cf. [l]). Of the major 
lipoxygenases in mammalian tissues (i.e. S-, 12- 
and 1 Slipoxygenases), the 5- and 1 Slipoxygenases 
are highly active metabolic pathways in human 
leukocytes [2]. Recently, interactions between the 
Abbreviations: LX, lipoxin; 15-HPETE, 15(s)- 
hydroperoxy-5,8,11-cis-13-trans-eicosatetraenoic acid; 
15-HETE, 15(S)-hydroxy-5,8,11-cis-13-trans-eicosa- 
tetraenoic acid; GC/MS, gas chromatography-mass 
spectrometry; UV, ultraviolet; RP-HPLC, reversed- 
phase high-performance liquid chromatography; MesSi, 
trimethylsilyl 
5- and 1Slipoxygenases have been found to lead to 
the formation of a novel series of eicosanoids 
[3,4]. The series contains a conjugated tetraene 
structure as a characteristic feature and has been 
termed the lipoxins [3,4]. Some of the lipoxins 
have been shown to possess biological activities. 
For example, in human neutrophils LXA 
stimulates superoxide anion generation [4] and 
both LXA and LXB inhibit the activities of human 
natural killer cells [5]. Moreover, LXA and LXB 
stimulate and modulate the enzymatic activities of 
isolated protein kinase C in vitro [6]. 
Recently, we have established the absolute 
stereochemistry of LXA and LXB as 
5(5’),6(R),15(S)-trihydroxy-7,9,13-trans-ll-cis-ei- 
cosatetraenoic acid and 5@),14(R),15(S)-trihy- 
droxyd, 10,12-trans+cis-eicosatetraenoic acid, re- 
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spectively [7,8]. Together with the determination 
of the absolute stereochemistries of LXA and 
LXB, evidence was presented for the transforma- 
tion of 15HETE acid into a 15(S)-hydroxy-5,6- 
oxido-7,9,13-trans-l l -cis-eicosatetraenoic acid in- 
termediate [7]. In this paper, further evidence for 
the existence of a 5(6)-epoxytetraene intermediate 
and its further enzymatic conversion is presented. 
methanol :water (70: 30, v/v) at 1 ml/min (UV 
detector set at 301 nm). Materials exhibiting the 
UV spectrum characteristic of tetraenes were col- 
lected separately, treated again with diazo- 
methane, and injected onto 
column (dp 5 pm, 4.6 mm x 
eluted with methanol :water 
1 ml/min (fig.1). 
2.5. Structure determinations 
2. MATERIALS AND METHODS 
2.1. Materials 
Materials and procedures employed were essen- 
tially the same as described in [3,4]. 
2.2. Cell preparation 
Human leukocytes were prepared from 
peripheral blood of healthy donors as in [9]. The 
preparations consisted of mixed populations of 
leukocytes where the neutrophil contribution 
represented >90%. Cells were washed twice and 
suspended in Dulbecco’s phosphate-buffered 
saline, pH 7.45. 
UV spectra were recorded with a Hewlett- 
Packard 8450A UV/visible spectrophotometer 
with methanol as a solvent. Catalytic hydrogena- 
tions were carried out as in [lo]. GC/MS was per- 
formed with a Dani 3800 gas chromatograph HR 
PRV-2CH equipped with a fused silica capillary 
column (0.32 mm x 20 m, Orion) SE-30, and 
7070E VG analytical mass spectrometer. The 
energy of the electron beam was set at 22.5 eV and 
the oven temperature at 230°C. Mass spectra were 
recorded using selective ion monitoring at m/e 
173. 
2.6. Purification of human liver cytosolic epoxide 
hydrolase 
2.3. Incubation conditions 
Leukocytes (100 x lo6 cells per ml, 20 ml) were 
warmed to 37’C in a shaking water bath. 
15-HETE (70pM) and the ionophore of divalent 
cations A23 187 (2.5 PM) were added 
simultaneously in ethanol (final concentration 
< l%, v/v) and 10 vols of either acidic ethanol or 
methanol were added after 30 s incubation. The 
pH values of the alcohols were lowered to 1 with 
HCl prior to their addition to the incubations. The 
samples were neutralized 2 min after the addition 
of the alcohol [lo]. 
A semipurified preparation of cytosolic epoxide 
hydrolase was obtained by column chromatog- 
raphy on DEAE-cellulose, phenyl-Sepharose and 
hydroxyapatite. 
2.4. Extraction and purification 
Samples were centrifuged and the supernatants 
(20 ml buffer and 200 ml alcohol) were evaporated 
under reduced pressure until approx. 20 ml was 
left in the flasks. Next, the samples were extracted 
with diethyl ether and subjected to silicic acid col- 
umn chromatography as in [lo]. Ethyl acetate frac- 
tions from silicic acid chromatography were 
evaporated, treated with diazomethane, and 
dissolved in methanol. Samples were injected onto 
an RP-HPLC column (Altex, ultrasphere-ODS, dp 
5 pm, 4.6 mm x 25 cm) and eluted with 
I I Jib 
30 20 10 
Fig.1. RP-HPLC chromatogram on Nucleosil Cl8 
(methanol :water; 70: 30, v/v) of trapping products 
treated with diazomethane from incubations of human 
leukocytes with 15HETE and A23187. The material was 
previously purified by ether extraction, silicic acid 
column chromatography and RP-HPLC (Altex 
ultrasphere-ODS, methanol :water; 70 : 30, v/v). Inset: 
UV spectrum of eluted material in methanol. 
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2.7. Incubation with the enzyme and extractions 
lOO/cl cytosolic epoxide hydrolase in argon- 
saturated 50 mM Tris-Cl (1.6 ng/ml, pH 8) was in- 
cubated at 37°C for 5 s with 50 PM 15(s)- 
hydroxy-5,6-oxido-7,9,13-trans-1 l cis-eicosatetra- 
enoic acid methyl ester added as an ethanol solu- 
tion. Reactions were stopped with 2 vols MeOH. 
Samples were extracted twice with 10 vols diethyl 
ether. After evaporation under argon, extracted 
material was redissolved in 50~1 methanol. 
Samples were injected onto an RP-HPLC column 
(Altex-ultrasphere-ODS, dp 5 pm, 4.6 mm x 
25 cm) and eluted with methanol :water (70: 30, 
v/v) at a flow rate of 1 ml/min (UV detector set at 
301 nm). 
3. RESULTS 
To provide further evidence for the existence of 
epoxytetraene intermediates in the biosynthesis of 
lipoxins alcohol trapping experiments were per- 
formed. Recent studies indicate that 15-HETE is 
also a precursor of LXA and LXB in activated 
human leukocytes [7,8]. Therefore, human 
leukocytes were incubated with 70 FM 15-HETE 
and 2.5 PM divalent cation ionophore A23187, 
and the incubations were stopped by addition of 
10 vols acidic ethanol or methanol. This procedure 
partially eliminated the trapping of non- 
enzymatically derived products which may be 
generated from 15-HPETE. Moreover, the addi- 
tion of 15-HETE excluded the formation of 
14(15)-epoxides. Trapping with either ethanol or 
methanol led to the appearance of tetraene con- 
taining compounds which were less polar than 
either lipoxins A and B or their naturally occurring 
isomers. To achieve further purification before 
structure determination, the ethanol-derived trap- 
ping products were subjected to two different RP- 
HPLC systems (see fig. 1). The UV spectrum of the 
material eluting with the retention time of 
28-29 min showed a triplet of absorption bands at 
288, 301 and 316 nm in methanol (see inset in 
fig. 1). 
To evaluate the structure of the trapping 
products obtained with ethanol, HPLC-purified 
material was converted to trimethylsilyl derivatives 
and analyzed by gas-liquid chromatography/mass 
spectrometry. The material eluted as a peak having 
an equivalent chain length corresponding to a C 
260 360 460 560 
Fig.2. Mass spectrum of the Me& derivative of an ethanol trapping product. 
300 400 500 
Fig.3. Mass spectrum at the MesSi derivative of a catalytically hydrogenated ethanol trapping product. 
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value of 23.5 (SE-30). Prominent ions in its mass 
spectrum were observed at m/e 173 (base 
peak; MesSiO+ = CH(CH&-CH$, and 203 
(Me&O+ = CH-(~H~)3-COOCH~) (fig.2). Ions at 
lower intensities were observed at m/e 171 
(203 - 32; elimination of CHsOH), 231 CH3- 
CHz-0-(MesSiO+) = CH-(CH-&-CH3, 275 (M - 
(173 + 90); loss of MesSiO+ = CH-(CH&-CH3 
plus MesSiOH), 307 (M - 231), 365 (M - 173), 438 
(M - 100; rearrangement followed by loss of 
O=HC-(CH&-CH3, and 448 (M - 90; loss of 
Me$SiOH). 
To gain further evidence for the structure of the 
parent compound, we next examined the mass 
spectrum of the product formed upon catalytic 
hydrogenation (fig.3) (C value 25.2 on SE-30). 
ions at high intensity were observed at 173 (base 
peak; Me3SiO” = CH-(CH&-CHJ), 203 (Me$iO+ = 
CH-(CH&-COOCH& 253 (M - (203 f 90); loss 
of ‘CH(OSiMe&(CH&-COOCH3 plus MejSiOH), 
283 (M - (173 +9O), loss of MeSiO’= CH- 
(CH&CH3 plus MesSiOH), 355 (M - (101 + 90); 
loss of ‘CH2-(CHz)z-COOCH3 plus Me$iO,H), 
373 (M - 173), loss of Me$iO+ = CH-(CH&CH& 
399, 425 (M - (90+ 31), loss of Me3SiOH plus 
CH30), 429 (M - (71+31+ 15); loss of 
‘(CH2)4-CHJ plus CH30 plus CH3), 446 (M - 100; 
rearrangement followed by loss of O=HC- 
(CH&-CHs), 456 (M - 90; loss of MeSiOH), and 
475 (M - 71; loss of ‘(CH&CH3). The presence 
of these ions in the mass spectra obtained for the 
Me3Si derivative of the unsaturated compound ant’ 
the product of hydrogenation are consistent with 
the assignment of the parent compound as 
5,15-dihydroxy-14-O-ethyl-6,8,10,12-eicosatetra- 
enoic acid. 
To gain further evidence for the enzymatic 
nature of LXA formation, 15(S)-hydroxy-5,6- 
epoxy-7,9,13-trans-l l-c~-eicosatetraenoic acid 
was prepared by total synthesis (Nicolaou, KC. et 
al., to be published) and was incubated with 
human liver cytosolic epoxide hydrolase. When 
added to epoxide hydrolase the epoxytetraene was 
rapidly and almost quantitatively converted into 
LXA (fig.4). In the absence of enzyme (i.e. buffer 
only) the 5,6-epoxytetraene hydrolyzed to a 
mixture of different lipoxin A and B isomers. In 
phosphate-buffered saline (pH 7.4), the half-life of 
the synthetic 5,6_epoxytetraene was less than 5 s as 
measured by a computer program with Hewfett- 
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Fig.4. A model for the enzymatic formation of LXA: 
transformation of a synthetic 5,6_epoxytetraene by 
human liver epoxide hydrolase. RP-HPLC chroma- 
togram on Altex ultrasphere-ODS (methanol : water; 
70: 30, v/v). 
Packard 8451A diode array spectrophotometer. 
4. DISCUSSION 
The lipoxins contain a conjugated tetraene struc- 
ture and the complete stereochemistry of the 
biologically active compounds (i.e. LXA and 
LXB) has recently been assigned [7,8]. In accor- 
dance with the results of “0 studies and the 
finding that 15-HETE is also a substrate for the 
biosynthesis of lipoxins A and B in activated 
human leukocytes it was proposed that once 
formed 5(~-hydroperoxy-15(~-hydroxyeicosa- 
tetraenoic acid is converted to a 15(S)-hydroxy- 
5,6-oxido-7,9,13-truns- 11 -cis-eicosatetraenoic acid 
intermediate [7]. This 5(6)-epoxytetraene may then 
serve as a common intermediate in both the en- 
zymatic biosynthesis of LXA and LXB and the 
formation of non-enzymatic hpoxin isomers [7,8]. 
To obtain further evidence for the existence of a 
5(6)-epoxytetraene, alcohol trapping experiments 
were performed with activated cells exposed to 
IS-HETE. Here, we report the isolation and the 
basic structure of the 15-HETE-derived 14-O- 
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alkyltetraene trapping products (e.g. 5,15-di- 
hydroxy-14-0-alkyleicosatetraenoic a ids). 
Samples of the trapping products were obtained 
by ether extraction, silicic acid column 
chromatography, and chromatography on two dif- 
ferent HPLC systems. Following HPLC the eluted 
material showed a triplet of absorption bands at 
288, 301 and 316 nm (methanol) indicating the 
presence of a conjugated tetraene. The presence of 
two hydroxyl groups, an alkyl group, and four 
conjugated double bonds was established by 
GUMS of the trimethylsilyl derivatives including 
the hydrogenated compound. In addition to the 
trapping product presented here some other 
tetraene containing trapping products were 
isolated (not shown). 
The present results clearly demonstrate the for- 
mation of 5,15dihydroxy- 14-O-alkyleicosatetra- 
enoic acid (upon addition of acidic alcohol) which 
in these studies serves as a marker of the 5(6)- 
epoxytetraene formation by leukocytes. Moreover, 
results obtained from the incubation of the syn- 
thetic 5,6-epoxytetraene with cytosolic epoxide 
hydrolase (fig.4) provide a clear model for the en- 
zymatic formation of LXA. However, it remains 
to be investigated if a similar enzyme is involved in 
the formation of LXA in human leukocytes. 
Others have also postulated the role of epox- 
ytetraenes in the formation of lipoxins and related 
compounds [13]. Results of the present study pro- 
vide evidence for the role of one possible 5(6)- 
epoxytetraene in the biosynthesis of lipoxins in 
human leukocytes. Taken together the results of 
these and previous studies [4,7,8] support the 
scheme of formation of LXA, LXB and their 
naturally occurring isomers presented in fig.5. 
Here, the 15(S)-hydroxy-5,6-oxido-7,9,13-trans- 
1 1-cis-eicosatetraenoic acid intermediate is trans- 
formed to LXB by attack at the C-14 position and 
generation of an 8-cis double bond. Alternatively, 
the 15(S)-hydroxy-5,6-oxido-7,9,13-trans-1 l-cis- 
eicosatetraenoic acid may be opened enzymatically 
by epoxide hydrolase into LXA. Other naturally 
occurring isomers may be formed by non-en- 
zymatic hydrolysis at the 5(6)-epoxytetraene or 
either work-up or hemoprotein-catalyzed iso- 
merizations [7,8]. 
15-HETE 
HQ OH 1 
Lym_______ ~CGQH __-____~ +-cmH 
6H 
6(S)-LXA / bH \ “Y.\ 
*cmH b 
6-tram-LXB 
5H 
Lipoxin A 
& 
Lipoxin B 
Fig.5. One possible biosynthetic pathway for lipoxin formation via a 15(S)-hydroxy-5,6-oxido-7,9,13-trans-1 I-& 
eicosatetraenoic acid. Note that the stereochemistry of all of the compounds shown has been determined [7,8]. 
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